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Abstract
Collimator angle is usually rotated when planning volumetric modulated arc therapy (VMAT)
due to the leakage of radiation between multi-leaf collimator (MLC) leaves. We studied the effect
of the collimator angles on the results of dosimetric verification of the VMAT plans for head and
neck patients. We studied VMAT plans for 10 head and neck patients. We made 2 sets of VMAT
plans for each patient. Each set was composed of 10 plans with collimator angles of 0, 5, 10, 15, 20,
25, 30, 35, 40, 45 degrees. Plans in the first set were optimized individually and plans in the second
set shared the 30 degree collimator angle optimization. Two sets of plans were verified using the
2-dimensional ion chamber array MatriXX (IBA Dosimetry, Germany). The comparison between
the calculation and measurements were made by the γ-index analysis. The γ-index (2%/2 mm) and
(3%/3 mm) passing rates had negative correlations with the collimator angle. Maximum difference
between γ-index (3%/3 mm) passing rates of different collimator angles for each patient ranged
from 1.46% to 5.60% with an average of 3.67%. There were significant differences (maximum 5.6%)
in the passing rates of different collimator angles. The results suggested that the accuracy of the
delivered dose depends on the collimator angle. These findings are informative when choosing a
collimator angle in VMAT plans.
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I. INTRODUCTION
Intensity modulated radiation therapy (IMRT) is usually used for head and neck cancer
patients because it delivers highly conformal radiation doses to the target with reduction
of toxicity to normal organs, as compared with conventional radiation therapy techniques
[1–6]. Volumetric modulated arc therapy (VMAT) is a novel IMRT technique. VMAT has
less MU, less treatment time, high quality planning and more efficiency than static gantry
angle IMRT [1–6]. During VMAT the linear accelerator (LINAC) control system changes the
dose rate and the multi leaf collimator (MLC) positions while gantry is rotating around the
patient. Collimator angle is usually rotated in the plans of VMAT to reduce radiation leakage
between MLC leaves. At a zero angle, the leakage between MLC leaves accumulates during
the gantry rotation and the summed leakage results in unwanted dose distributions, which
can not be controlled by optimization. At different collimator angles, the unwanted doses
can be controlled by dose constraints in the optimization procedure so that we can reduce
the unwanted doses. The optimal collimator angle for VMAT plan is thus required to be
determined. There are several factors for consideration in the choice of the collimator angle
of the VMAT plan. Among them we concentrated on the accuracy of the VMAT delivery.
We studied the effect of the collimator angle on the results of dosimetric verifications of the
VMAT plan for nasopharyngeal cancer (NPC).
II. MATERIALS AND METHODS
Ten patients with late-stage nasopharyngeal cancer were treated with concurrent chemo
radiation therapy (CCRT). Eight patients had Stage III disease and 2 patients had Stage
IV disease according to American Joint Committee on Cancer staging system 7. Nine pa-
tients were male and 1 patient was female. One radiation oncologist delineated radiation
targets and organs at risk (OARs). The clinical target volume (CTV) included the primary
nasopharyngeal tumor, neck nodal region and subclinical disease. Considering the setup
uncertainty, margins ranging from 3-10 mm were added to each CTV to create a planning
target volume (PTV). Reduced-field techniques were used for delivery of the 66-70 Gy to-
tal dose. The treatment plan course for each patient consisted of several sub-plans. In
this study, we selected the first plan with prescribed doses of 50-60 Gy in 25-30 fractions
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to study the effect of the collimator angles on dosimetric verifications of the VMAT. The
radiation treatment planning system Eclipse V10.0.42 (Varian Medical Systems, USA) was
used to generate VMAT plans. The VMAT (RapidArc: Varian) plans were generated for
Clinac IX linear accelerator using 6 MV photons. The Clinac IX is equipped with a Millen-
nium 120 MLC that has spatial resolution of 5 mm at the isocenter for the central 20 cm
region and of 10 mm in the outer 2×10 cm region. The maximum MLC leaf speed is 2.5
cm/s and leaf transmission is 1.8%. Dosimetric leaf gap of the MLC was measured using
the procedure recommended by Varian Medical Systems. The value of the dosimetric leaf
gap was 1.427 mm for 6 MV photons. For volume dose calculation, grid size of 2.5 mm,
inhomogeneiy correction, the Anisotropic Analytical Algorithm (AAA) V10.0.28 and the
Progressive Resolution Optimizer (PRO) V10.0.28 were used in all plans. VMAT plans for
NPC patients were composed of 2 coplanar full arcs in 181-179 degree clockwise and 179-181
degree counterclockwise directions. The 2 full-arc delivery was expected to achieve better
target coverage and conformity than the single arc [7]. We generated 10 VMAT plans (plan
set A) with different collimator angles for each patient. Ten collimator angles for the first arc
were 0, 5, 10, 15, 20, 25, 30, 35, 40 and 45 degrees. For the second arc, the collimator angle
was selected explementary to the collimator angle of the first arc in the same plan, i.e., the
2 collimator angles added up to 360 degree. The average field size of VMAT plans was 22 ×
22 cm2. We used the same dose constraints for all the 10 VMAT plans and optimization was
conducted for each plan. The maximum dose rate was 600 MU/min. The target coverage
was aimed to achieve a 100% volume covered by 95% of prescribed dose. Optimization of
each plan resulted in different fluences and different MLC motions for each plan. Therefore
we had 2 variables, i.e., the collimator angle and MLC motions. To simplify the analysis we
generated another set of 10 plans (plan set B) with the same MLC motions and different
collimator angles for each patient. The MLC motions were those of the plan with 30 degree
collimator angle. The plans in this set had different dose distributions and usually can not
be used for treatment purposes excepting the plan with a 30 degree collimator angle.
We performed patient specific quality assurances (QA) of 2 sets of 10 VMAT plans for each
patient. The measurements were made by the 2-dimensional ion chamber array MatriXX
(IBA Dosimetry, Germany) [8]. The MatriXX has 1020 pixel ion chambers arranged in a
32×32 matrix covering 24.4×24.4 cm2. Each ion chamber has the following dimensions:
4.5 mm in diameter, 5 mm in height and a sensitive volume of 0.08 cm3. The distance
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FIG. 1: Measurement devices (MatriXX, MultiCube and gantry angle sensor) set-up on the treat-
ment couch for patient specific quality assurances of VMAT plans.
FIG. 2: Axial CT images of the MatriXX placed between solid water phantoms.
between chambers is 7.619 mm. The MatriXX has an intrinsic buildup and backscatter
thicknesses of 0.3 mm and 3.5 mm, respectively. The MatriXX was placed between solid
water phantoms MultiCube (IBA Dosimetry, Germany) (Figure 1) so that thickness of total
buildup and backscatter was 5 cm (Figure 2). The source to surface distance was 95 cm
with the measurement plane of the MatriXX at the isocenter of the LINAC. Measurement
was done for each arc in the plan; therefore, we conducted 40 measurements for each patient
and the total number of measurements was 400. The angular dependence of the MatriXX
was corrected after the measurements using the gantry angle sensor [9] (IBA Dosimetry,
Germany). The comparison between the calculations and the measurements were made by γ-
index (2%/2 mm, 3%/3 mm) analysis [10–12] using OmniPro IMRT V1.7b (IBA Dosimetry,
Germany). The γ-index was calculated only for the regions that have dose values above 10%
[13] in the measured area.
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TABLE I: γ-index passing rates of the patient specific QAs as a function of the collimator angle
Collimator Plan set A Plan set B
angle 2%/2 mm 3%/3 mm 2%/2 mm 3%/3 mm
0 91.87±3.45% 97.32±1.74% 87.95±5.35% 97.07±2.36%
5 91.86±3.39% 97.59±1.77% 87.37±4.66% 96.81±2.02%
10 91.65±3.16% 97.63±1.41% 87.00±4.67% 97.05±1.61%
15 90.75±3.17% 97.46±1.57% 86.82±5.20% 96.60±2.15%
20 90.64±3.69% 97.41±1.45% 85.86±5.20% 95.86±2.66%
25 89.93±3.70% 97.05±1.74% 83.97±5.74% 94.70±2.84%
30 89.52±2.92% 96.76±1.65% 83.45±6.35% 94.13±3.11%
35 87.73±4.39% 95.94±1.91% 84.00±6.21% 94.53±3.16%
40 87.06±4.19% 95.87±1.49% 84.09±6.35% 94.53±3.35%
45 85.37±5.18% 95.19±1.76% 83.95±6.41% 94.29±3.44%
III. RESULTS AND DISCUSSION
Average γ-index passing rates of patient specific QAs were given in Table I. The results
were averaged over the 2 arcs and 10 patients. Because the 2 arcs in each VMAT plan
rotated almost 360 degrees and the measurement set-up is mirror symmetric about the
measurement plane (y = 0 plane in Figure 2) of the MatriXX detector and a vertical plane
passing through the isocenter (x = 0 plane in Figure 2) the arc with collimator angle θ is
symmetric to the arc with collimator angle 360 − θ. Therefore we regarded the collimator
angle of the second arc, which was equal to 360 minus the collimator angle of the first arc,
as the collimator angle of the first arc in the analysis. Maximum difference between γ-index
(2%/2 mm) passing rates of plans in plan set A for each patient ranged from 2.83% to
14.32% and the average value was 8.44±4.24%. Using the 3%/3 mm criteria the maximum
difference ranged from 1.46% to 5.60% and the average value was 3.67±1.29%. Maximum
difference between γ-index (2%/2 mm) passing rates of plans in plan set B for each patient
ranged from 3.71% to 10.44% and the average value was 7.97±2.17%. Using the 3%/3 mm
criteria the maximum difference ranged from 1.46% to 7.23% and the average value was
4.69±2.51%. 2-dimensional dose distributions calculated by the Eclipse treatment planning
5
FIG. 3: Results for 1 patient plan in the plan set A for collimator angle 5. The first figure is the
2-dimensional dose distribution calculated by the Eclipse treatment planning system. The second
one is the dose distribution measured by the MatriXX detector. The last one is the γ-index (3%/3
mm) distributions. In the γ-index distributions red color indicates the region where the 3%/3 mm
criteria failed.
FIG. 4: Results for 1 patient (same patient in Figure 3) plan in the plan set A for collimator angle
35. The first figure is the 2-dimensional dose distribution calculated by the Eclipse treatment
planning system. The second one is the dose distribution measured by the MatriXX detector. The
last one is the γ-index (3%/3 mm) distributions. In the γ-index distributions red color indicates
the region where the 3%/3 mm criteria failed.
system, dose distributions measured by the MatriXX detector and γ-index (3%/3 mm)
distributions of 1 patient plans in the plan set A for collimator angle 5 and 35 degree
were shown in Figure 3 and 4, respectively. The passing rate for the 35 degree collimator
angle was less than the passing rate for the 5 degree collimator angle. The increase in
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FIG. 5: Average normalization values for the γ-index passing rates (2%/ 2 mm) of patient specific
delivery QAs as a function of the collimator angle.
collimator angle resulted in decreased γ-index passing rates, as shown in Figure 5. In the
Figure, passing rates were normalized to the value of 0 degree. Black and white squares
indicated γ-index (2%/2 mm) and (3%/3 mm) passing rates, respectively, averaged over
plan set A. Black and white triangles indicated γ-index (2%/2 mm) and (3%/3 mm) passing
rates, respectively, averaged over plan set B. There were statistically significant negative
correlations between the collimator angle and the γ-index passing rates. Pearson correlation
coefficients for pair-wise ratings of the γ-index (2%/2 mm) and (3%/3 mm) passing rates of
plans in the plan set A and B were -0.524 and -0.412, respectively with p-values < 0.001.
For accuracy of VMAT a smaller collimator angle is better, and for MLC leakage a larger
collimator angle is better, we were thus required to make a compromise. Based on this study,
in our hospital the collimator angles of the VMAT plans for head and neck patients range
between 15-25 degrees because the average γ-index passing rates were above or near to 90%
for the 2%/2 mm criteria and 97% for the 3%/3 mm criteria, as shown in the results of the
passing rates for the plan set A (Table I). In other hospitals these results can be somewhat
different because they have different VMAT delivery systems and diffterent VMAT planning
systems. We think that they can find optimal collimator angles by conducting the similar
measurements described in this article.
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Although not included in this article, we performed the patient specific QAs for other
treatment sites with smaller field sizes that are < 13 × 13 cm2. Maximum difference of the
passing rates for VMAT plans with various collimator angles was < 1.5%. Collimator angle
does not affect the accuracy of the VMAT delivery with small field sizes.
The accuracy of radiation delivery by the LINAC depends on geometrical accuracies
such as gantry isocentricity, collimator isocentricity and MLC position. It was reported that
leaf limiting velocity, MLC position and mechanical isocenter varied at different collimator
and gantry angles [14, 15]. This may explain the γ-index passing rates dependence on the
collimator angle. Further study is needed to investigate the origin of the collimator angle
dependence of the accuracy of VMAT delivery.
The quality of the plan itself is another factor for consideration in the choice of the
collimator angle of the VMAT plan. Optimized dose distributions with the same dose
constraints can vary according to the collimator angle of the VMAT plan. Further study is
needed to evaluate the quality of VMAT plans with different collimator angles.
IV. CONCLUSIONS
We found that the results of the patient specific QAs for VMAT plans using the 2-
dimensional ion chamber array MatriXX are dependent on the collimator angle of the VMAT
plans. The γ-index (2%/2 mm) and (3%/3 mm) passing rates were negatively correlated
with the collimator angle. We showed that collimator angles of the VMAT plans for head and
neck cancer patients range between 15-25 degrees resulting in the average γ-index passing
rates above or near to 90% for the 2%/2 mm criteria and 97% for the 3%/3 mm criteria.
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